Citations to this article
Julien Fourcade, … , Alan J. Korman, Hassane M. Zarour
Published July 25, 2018
Citation Information: JCI Insight. 2018;3(14):e121157. https://doi.org/10.1172/jci.insight.121157.
Citation Information: JCI Insight. 2018;3(14):e121157. https://doi.org/10.1172/jci.insight.121157.
Abstract
CD4+ Tregs impede T cell responses to tumors. They express multiple inhibitory receptors that support their suppressive functions, including T cell Ig and ITIM domain (TIGIT). In melanoma patients, we show that Tregs exhibit increased TIGIT expression and decreased expression of its competing costimulatory receptor CD226 as compared with CD4+ effector T cells, resulting in an increased TIGIT/CD226 ratio. Tregs failed to upregulate CD226 upon T cell activation. TIGIT+ Tregs are highly suppressive, stable, and enriched in tumors. TIGIT and CD226 oppose each other to augment or disrupt, respectively, Treg suppression and stability. A high TIGIT/CD226 ratio in Tregs correlates with increased Treg frequencies in tumors and poor clinical outcome upon immune checkpoint blockade. Altogether, our findings show that a high TIGIT/CD226 ratio in Tregs regulates their suppressive function and stability in melanoma. They provide the rationale for novel immunotherapies to activate CD226 in Tregs together with TIGIT blockade to counteract Treg suppression in cancer patients.
Authors
Julien Fourcade, Zhaojun Sun, Joe-Marc Chauvin, Mignane Ka, Diwakar Davar, Ornella Pagliano, Hong Wang, Sofiane Saada, Carmine Menna, Rada Amin, Cindy Sander, John M. Kirkwood, Alan J. Korman, Hassane M. Zarour
Total citations by year
Citation information
Citations to this article (103)
| Title and authors | Publication | Year |
|---|---|---|
|
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen BH, Ali BR, Elkord E |
Molecular Cancer | 2025 |
|
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano A, Lau HS, Carter LM, Lee EH, Lam HY, Okina E, Tan DJ, Tan W, Ang HL, Carbone D, Yee MY, Shanmugam MK, Huang XZ, Sethi G, Tan TZ, Lim LH, Huang RY, Ungefroren H, Giovannetti E, Tang DG, Bruno TC, Luo P, Andersen MH, Qian BZ, Ishihara J, Radisky DC, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper KA, Shi T, Merghoub T, Krebs S, Kusumbe AP, Davids MS, Brown JR, Kumar AP |
Journal of Hematology & Oncology | 2025 |
|
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y, Yu J |
Biomarker Research | 2024 |
|
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W, Won T, Daoud A, Čiháková D |
Frontiers in immunology | 2024 |
|
LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation
Joller N, Anderson AC, Kuchroo VK |
Immunity | 2024 |
|
Loss of chromosome Y in regulatory T cells
Mattisson J, Halvardson J, Davies H, Bruhn-Olszewska B, Olszewski P, Danielsson M, Bjurling J, Lindberg A, Zaghlool A, Rychlicka-Buniowska E, Dumanski JP, Forsberg LA |
BMC Genomics | 2024 |
|
Lymphatic endothelial cell-mediated accumulation of CD177+Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma
Ma M, Li L, Yang SH, Huang C, Zhuang W, Huang S, Xia X, Tang Y, Li Z, Zhao ZB, Chen Q, Qiao G, Lian ZX |
OncoImmunology | 2024 |
|
Single-cell RNA sequencing unveils tumor heterogeneity and immune microenvironment between subungual and plantar melanoma.
Wang P, Ma Y, Zhao Y, Li Y, Tang C, Wang S, Jin S, Wang J, Zhu M, Xie B, Wang P |
Scientific Reports | 2024 |
|
CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
Mu Y, Guan X |
Current medicinal chemistry | 2024 |
|
Many Faces of Regulatory T Cells: Heterogeneity or Plasticity?
Blinova VG, Zhdanov DD |
Cells | 2024 |
|
Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.
Jo Y, Sim HI, Yun B, Park Y, Jin HS |
Experimental & molecular medicine | 2024 |
|
TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes
Zhong T, Li X, Lei K, Tang R, Deng Q, Love PE, Zhou Z, Zhao B, Li X |
Nature Communications | 2024 |
|
CD34(+) and CD34(-) MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34(+) MM cells.
Fukui-Morimoto A, Serizawa K, Fujimoto K, Hanamoto A, Iwata Y, Kakutani H, Kumode T, Hirase C, Morita Y, Tatsumi Y, Hanamoto H, Tanaka H, Matsumura I |
International journal of hematology | 2024 |
|
A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion.
Wei X, Zhao L, Yang F, Yang Y, Zhang H, Du K, Tian X, Fan R, Si G, Wang K, Li Y, Wei Z, He M, Sui J |
Molecular therapy : the journal of the American Society of Gene Therapy | 2024 |
|
Single‐cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers
Yang C, Qu J, Wu J, Cai S, Liu W, Deng Y, Meng Y, Zheng L, Zhang L, Wang L, Guo X |
Clinical and Translational Medicine | 2024 |
|
TIGIT+ CD4+ regulatory T cells enhance PD-1 expression on CD8+ T cells and promote tumor growth in a murine ovarian cancer model
Chen F, Xu Y, Liu X, Dong N, Tian L |
Journal of Ovarian Research | 2024 |
|
Identification and classification of distinct surface markers of T regulatory cells
Wegrzyn AS, Kedzierska AE, Obojski A |
Frontiers in immunology | 2023 |
|
Treg-specific CD226 Deletion Reduces Diabetes Incidence in NOD Mice by Improving Regulatory T Cell Stability
Puchong Thirawatananond, Matthew Brown, Lindsey Sachs, Juan M. Arnoletti, Wen-I Yeh, Amanda Posgai, Melanie Shapiro, Yi-Guang Chen, Todd Brusko |
Diabetes | 2023 |
|
The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity
Saha S, Sparkes A, Matus EI, Lee P, Gariépy J |
Scientific Reports | 2023 |
|
Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction.
Gong L, Luo J, Zhang Y, Yang Y, Li S, Fang X, Zhang B, Huang J, Chow LK, Chung D, Huang J, Huang C, Liu Q, Bai L, Tiu YC, Wu P, Wang Y, Tsao GS, Kwong DL, Lee AW, Dai W, Guan XY |
Nature Communications | 2023 |
|
Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma
Xia QD, Li B, Sun JX, Liu CQ, Xu JZ, An Y, Xu MY, Zhang SH, Zhong XY, Zeng N, Ma SY, He HD, Zhang YC, Guan W, Li H, Wang SG |
Frontiers in Oncology | 2023 |
|
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, Gogas H |
Cancers | 2023 |
|
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Chu X, Tian W, Wang Z, Zhang J, Zhou R |
Molecular Cancer | 2023 |
|
TIGIT-based immunotherapeutics in lung cancer
Patel AJ, Middleton GW |
2023 | |
|
Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms.
Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J, Meng L, Xin Y, Jiang X |
Cell & Bioscience | 2023 |
|
TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
Heiduk M, Klimova A, Reiche C, Digomann D, Beer C, Aust DE, Distler M, Weitz J, Seifert AM, Seifert L |
Clinical cancer research | 2023 |
|
TIGIT, a novel immune checkpoint therapy for melanoma.
Tang W, Chen J, Ji T, Cong X |
Cell Death and Disease | 2023 |
|
Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature
Yadav R, Hakobyan N, Wang JC |
International journal of molecular sciences | 2023 |
|
Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P, Sun W |
Journal of Cancer Research and Clinical Oncology | 2023 |
|
TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation
Worboys JD, Vowell KN, Hare RK, Ambrose AR, Bertuzzi M, Conner MA, Patel FP, Zammit WH, Gali-Moya J, Hazime KS, Jones KL, Rey C, Jonjic S, Rovis TL, Tannahill GM, Cruz De Matos GD, Waight JD, Davis DM |
Nature Communications | 2023 |
|
Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma.
Lee SH, Kim SH, Nam TM, Jang JH, Kim KH, Lee YS, Kim MS, Kim MS, Jin SY, Lee M, Lee SH, Kim YZ |
Journal of Korean Medical Science | 2023 |
|
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy D, Gilmour C, Patnaik S, Wang LL |
Frontiers in immunology | 2023 |
|
Fcγ receptors and immunomodulatory antibodies in cancer.
Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS, Litchfield K, Quezada SA |
Nature reviews. Cancer | 2023 |
|
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH, Najjar YG |
Nature reviews. Immunology | 2023 |
|
Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy.
Miraki Feriz A, Bahraini F, Khosrojerdi A, Azarkar S, Sajjadi SM, HosseiniGol E, Honardoost MA, Saghafi S, Silvestris N, Leone P, Safarpour H, Racanelli V |
PloS one | 2023 |
|
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non–small cell lung cancer
Villaruz LC, Blumenschein GR Jr, Otterson GA, Leal TA |
Cancer | 2023 |
|
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
X Chen, L Xue, X Ding, J Zhang, L Jiang, S Liu, H Hou, B Jiang, L Cheng, Q Zhu, L Zhang, X Zhou, J Ma, Q Liu, Y Li, Z Ren, B Jiang, X Song, J Song, W Jin, M Wei, Z Shen, X Liu, L Wang, K Li, T Zhang |
Frontiers in immunology | 2022 |
|
DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
D Niebel, A Fröhlich, R Zarbl, S Fietz, L de Vos, T Vogt, J Dietrich, J Sirokay, P Kuster, G Saavedra, S Valladolid, F Hoffmann, S Strieth, J Landsberg, D Dietrich |
Clinical Epigenetics | 2022 |
|
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
E Chiang, I Mellman |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
X Chen, W Zhang, W Yang, M Zhou, F Liu |
Aging | 2022 |
|
Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
D Wang, Y Gu, X Yan, C Huo, G Wang, Y Zhao, M Teng, Y Li |
Frontiers in Oncology | 2022 |
|
Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
K Park, M Veena, D Shin |
Frontiers in Cell and Developmental Biology | 2022 |
|
Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives
A Alberti, P Bossi |
Frontiers in Oncology | 2022 |
|
CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells
M Yasutomi, A Christiaansen, N Imai, N Martin-Orozco, C Forst, G Chen, H Ueno |
Frontiers in immunology | 2022 |
|
Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity
Z Jiang, H Zhu, P Wang, W Que, L Zhong, X Li, F Du |
2022 | |
|
Update in TIGIT Immune-Checkpoint Role in Cancer
Annese T, Tamma R, Ribatti D |
Frontiers in Oncology | 2022 |
|
Expression of CD226 is upregulated on Tr1 cells from neuromyelitis optica spectrum disorder patients
Chen P, Wu M, Wang N, Xia F, Du F, Liu Z, Wang J, Jin J, Jin B, Zhao G, Chen L, Yi J, Fang L |
Brain and Behavior | 2022 |
|
The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients
Del Bello A, Gouin A, Chaubet C, Kamar N, Treiner E |
Scientific Reports | 2022 |
|
Natural Killer cells demonstrate distinct eQTL and transcriptome-wide disease associations, highlighting their role in autoimmunity
Gilchrist JJ, Makino S, Naranbhai V, Sharma PK, Koturan S, Tong O, Taylor CA, Watson RA, de los Aires AV, Cooper R, Lau E, Danielli S, Hameiri-Bowen D, Lee W, Ng E, Whalley J, Knight JC, Fairfax BP |
Nature Communications | 2022 |
|
Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
Mussafi O, Mei J, Mao W, Wan Y |
Frontiers in Oncology | 2022 |
|
Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models
Franks SE, Fabian KP, Santiago-Sánchez G, Wolfson B, Hodge JW |
OncoImmunology | 2022 |
|
TIGIT Expression on Intratumoral Lymphocytes Correlates with Improved Prognosis in Oral Squamous Cell Carcinoma
Eichberger J, Spoerl S, Spanier G, Erber R, Taxis J, Schuderer J, Ludwig N, Fiedler M, Nieberle F, Ettl T, Geppert CI, Reichert TE, Spoerl S |
Biomedicines | 2022 |
|
T-Cell Mediated Immunity in Merkel Cell Carcinoma
Ouyang K, Zheng DX, Agak GW |
Cancers | 2022 |
|
TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
Jin S, Zhang Y, Zhou F, Chen X, Sheng J, Zhang J |
Frontiers in Oncology | 2022 |
|
TIGIT axis: novel immune checkpoints in anti-leukemia immunity.
Qiu D, Liu X, Wang W, Jiang X, Wu X, Zheng J, Zhou K, Kong X, Wu X, Jin Z |
Clinical and Experimental Medicine | 2022 |
|
IL-35 promotes CD4+Foxp3+ Treg and inhibits atherosclerosis via maintaining CCR5-amplified Treg suppressive mechanisms
Ying Shao, William Y Yang, Fatma Saaoud, Charles Drummer IV, Yu Sun, Keman Xu, Yifan Lu, Huimin Shan, Ethan Shevach, Xiaohua Jiang, Hong Wang, Xiaofeng Yang |
JCI Insight | 2021 |
|
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy
B Wu, C Zhong, Q Lang, Z Liang, Y Zhang, X Zhao, Y Yu, H Zhang, F Xu, Y Tian |
Journal of Experimental & Clinical Cancer Research | 2021 |
|
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
J Yeo, M Ko, DH Lee, Y Park, H Jin |
Pharmaceuticals (Basel, Switzerland) | 2021 |
|
DNAM-1 regulates Foxp3 expression in regulatory T cells by interfering with TIGIT under inflammatory conditions
K Sato, Y Yamashita-Kanemaru, F Abe, R Murata, Y Nakamura-Shinya, K Kanemaru, M Muratani, A Veillette, M Goto, M Ito, A Shibuya, K Shibuya |
Proceedings of the National Academy of Sciences | 2021 |
|
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Z Ge, MP Peppelenbosch, D Sprengers, J Kwekkeboom |
Frontiers in immunology | 2021 |
|
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
S Kawashima, T Inozume, M Kawazu, T Ueno, J Nagasaki, E Tanji, A Honobe, T Ohnuma, T Kawamura, Y Umeda, Y Nakamura, T Kawasaki, Y Kiniwa, O Yamasaki, S Fukushima, Y Ikehara, H Mano, Y Suzuki, H Nishikawa, H Matsue, Y Togashi |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Targeting regulatory T cells for immunotherapy in melanoma
L Huang, Y Guo, S Liu, H Wang, J Zhu, L Ou, X Xu |
2021 | |
|
The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity
YS Hsu, KL Lu, Y Fu, CW Wang, CW Lu, YF Lin, WC Chang, KY Yeh, SI Hung, WH Chung, CB Chen |
Frontiers in immunology | 2021 |
|
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
M Martinez, S Kim, NS Jean, S OBrien, L Lian, J Sun, RI Verona, E Moon |
OncoImmunology | 2021 |
|
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade
K Hansen, S Kumar, K Logronio, S Whelan, S Qurashi, HY Cheng, A Drake, M Tang, P Wall, D Bernados, L Leung, E Ophir, Z Alteber, G Cojocaru, M Galperin, M Frenkel, M White, J Hunter, SC Liang, MF Kotturi |
Cancer Immunology, Immunotherapy | 2021 |
|
Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 Expression and Rapid Membrane Vitamin D Signaling Pathway
M Fraga, M Yáñez, M Sherman, F Llerena, M Hernandez, G Nourdin, F Álvarez, J Urrizola, C Rivera, L Lamperti, L Nova, S Castro, O Zambrano, A Cifuentes, L Campos, S Moya, Juan, M Nuñez, J Gatica, J Figueroa, F Zúñiga, C Salomón, G Cerda, R Puentes, G Labarca, M Vidal, R McGregor, E Nova-Lamperti |
Frontiers in immunology | 2021 |
|
A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment
J Wen, X Mao, Q Cheng, Z Liu, F Liu |
Scientific Reports | 2021 |
|
A Dynamic Transcriptome Map of Different Tissue Microenvironment Cells Identified During Gastric Cancer Development Using Single-Cell RNA Sequencing
H Yin, R Guo, H Zhang, S Liu, Y Gong, Y Yuan |
Frontiers in immunology | 2021 |
|
Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer
W Tan, M Liu, L Wang, Y Guo, C Wei, S Zhang, C Luo, N Liu |
BMC Cancer | 2021 |
|
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors
Y Li, Y Zhang, G Cao, X Zheng, C Sun, H Wei, Z Tian, W Xiao, R Sun, H Sun |
Journal of Hematology & Oncology | 2021 |
|
Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer
S Sivakumar, E Abu-Shah, DJ Ahern, EH Arbe-Barnes, AK Jainarayanan, N Mangal, S Reddy, A Rendek, A Easton, E Kurz, M Silva, Z Soonawalla, LR Heij, R Bashford-Rogers, MR Middleton, ML Dustin |
Cancers | 2021 |
|
Establishment of a novel ferroptosis-related lncRNA pair prognostic model in colon adenocarcinoma
H Li, L Liu, T Huang, M Jin, Z Zheng, H Zhang, M Ye, K Liu |
Aging | 2021 |
|
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer
C Chuckran, A Cillo, J Moskovitz, A Overacre-Delgoffe, A Somasundaram, F Shan, G Magnon, S Kunning, I Abecassis, A Zureikat, J Luketich, A Pennathur, J Sembrat, M Rojas, D Merrick, S Taylor, B Orr, F Modugno, R Buckanovich, R Schoen, S Kim, U Duvvuri, H Zeh, R Edwards, J Kirkwood, L Coffman, R Ferris, T Bruno, D Vignali |
Science Translational Medicine | 2021 |
|
Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
Jin HS, Park Y |
BMB Reports | 2021 |
|
LncRNA MIR155HG functions as a ceRNA for inhibition of lung adenocarcinoma growth and prediction of prognosis
Wang J, Li J |
Archives of Medical Science : AMS | 2021 |
|
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
JM Chauvin, M Ka, O Pagliano, C Menna, Q Ding, R DeBlasio, C Sanders, J Hou, XY Li, S Ferrone, D Davar, JM Kirkwood, RJ Johnston, AJ Korman, MJ Smyth, HM Zarour |
Clinical cancer research | 2020 |
|
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
A Schnell, L Bod, A Madi, VK Kuchroo |
Cell Research | 2020 |
|
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
CA Chuckran, C Liu, TC Bruno, CJ Workman, DA Vignali |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Targeting novel inhibitory receptors in cancer immunotherapy
QQ Ding, JM Chauvin, HM Zarour |
Seminars in Immunology | 2020 |
|
TIGIT in cancer immunotherapy
JM Chauvin, HM Zarour |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
JH Han, M Cai, J Grein, S Perera, H Wang, M Bigler, R Ueda, TW Rosahl, E Pinheiro, D LaFace, W Seghezzi, SM Williams |
Frontiers in immunology | 2020 |
|
Alternative Checkpoints as Targets for Immunotherapy
A Pant, R Medikonda, M Lim |
Current Oncology Reports | 2020 |
|
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
S Jeong, SH Park |
Immune Network | 2020 |
|
CD226: An Emerging Role in Immunologic Diseases
Z Huang, G Qi, JS Miller, SG Zheng |
Frontiers in Cell and Developmental Biology | 2020 |
|
Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models
A Volpe, C Lang, L Lim, F Man, E Kurtys, C Ashmore-Harris, P Johnson, E Skourti, RT de Rosales, GO Fruhwirth |
Molecular Therapy | 2020 |
|
CD226 attenuates Treg suppressive capacity via CTLA-4 and TIGIT during EAE
N Wang, S Liang, J Jin, L Fang, Q Ma, X Wang, Y Song, L Chen |
Immunologic Research | 2020 |
|
CD226 Attenuates Treg Proliferation via Akt and Erk Signaling in an EAE Model
N Wang, H Yi, L Fang, J Jin, Q Ma, YS Shen, J Li, S Liang, J Xiong, Z Li, H Zeng, F Jiang, B Jin, L Chen |
Frontiers in immunology | 2020 |
|
Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma
HR Koshkaki, S Minasi, A Ugolini, G Trevisi, C Napoletano, IG Zizzari, M Gessi, F Giangaspero, A Mangiola, M Nuti, FR Buttarelli, A Rughetti |
Journal of Personalized Medicine | 2020 |
|
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer
NG Steele, ES Carpenter, SB Kemp, VR Sirihorachai, S The, L Delrosario, J Lazarus, ED Amir, V Gunchick, C Espinoza, S Bell, L Harris, F Lima, V Irizarry-Negron, D Paglia, J Macchia, AK Chu, H Schofield, EJ Wamsteker, R Kwon, A Schulman, A Prabhu, R Law, A Sondhi, J Yu, A Patel, K Donahue, H Nathan, C Cho, MA Anderson, V Sahai, CA Lyssiotis, W Zou, BL Allen, A Rao, HC Crawford, F Bednar, TL Frankel, MP di Magliano |
2020 | |
|
Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients
Z Jin, W Ye, T Lan, Y Zhao, X Liu, J Chen, J Lai, S Chen, X Zhong, X Wu |
BioMed Research International | 2020 |
|
TIGIT signaling restores suppressor function of Th1-Tregs
Liliana E Lucca, Pierre-Paul Axisa, Emily R Singer, Neal Nolan, Margarita Dominguez-Villar, David Hafler |
JCI Insight | 2019 |
|
Regulation of regulatory T cells in cancer
J Stockis, R Roychoudhuri, TY Halim |
Immunology | 2019 |
|
Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity
H Yano, LP Andrews, CJ Workman, DA Vignali |
Immunology | 2019 |
|
Biomarkers for Immunotherapy of Cancer: Methods and Protocols
M Thurin, A Cesano, FM Marincola |
2019 | |
|
TIGIT as an emerging immune checkpoint
H Harjunpää, C Guillerey |
Clinical & Experimental Immunology | 2019 |
|
Fine tuning of the DNAM-1/TIGIT/ligand axis in mucosal T cells and its dysregulation in pediatric inflammatory bowel diseases (IBD)
S Battella, S Oliva, L Franchitti, RL Scaleia, A Soriani, S Isoldi, C Capuano, C Pighi, S Morrone, R Galandrini, A Santoni, G Palmieri |
Mucosal Immunology | 2019 |
|
HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules
C Ackermann, M Smits, R Woost, JM Eberhard, S Peine, S Kummer, M Marget, T Kuntzen, WW Kwok, AW Lohse, T Jacobs, T Boettler, JS zur Wiesch |
Scientific Reports | 2019 |
|
Insights in the immunobiology of glioblastoma
D Strepkos, M Markouli, A Klonou, C Piperi, AG Papavassiliou |
Journal of Molecular Medicine | 2019 |
|
The Discovery of Biomarkers in Cancer Immunotherapy
AP George, TM Kuzel, Y Zhang, B Zhang |
Computational and Structural Biotechnology Journal | 2019 |
|
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
PA Ascierto, C Bifulco, L Buonaguro, LA Emens, RL Ferris, BA Fox, GM Delgoffe, J Galon, C Gridelli, M Merlano, P Nathan, K Odunsi, H Okada, CM Paulos, S Pignata, KA Schalper, S Spranger, G Tortora, H Zarour, LH Butterfield, I Puzanov |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Human regulatory T cells (Treg) and their response to cancer
TL Whiteside |
Expert Review of Precision Medicine and Drug Development | 2019 |
|
TIGIT: a novel immunotherapy target moving from bench to bedside
Solomon BL, Garrido-Laguna I |
Cancer Immunology, Immunotherapy | 2018 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
